Roivant Sciences Ltd.

NasdaqGS ROIV

Roivant Sciences Ltd. Revenue for the year ending March 31, 2024: USD 124.80 M

Roivant Sciences Ltd. Revenue is USD 124.80 M for the year ending March 31, 2024, a 0.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Roivant Sciences Ltd. Revenue for the year ending March 31, 2024 was USD 124.80 M, a 103.65% change year over year.
Roivant Sciences Ltd. Revenue for the year ending March 31, 2023 was USD 61.28 M, a 10.84% change year over year.
Roivant Sciences Ltd. Revenue for the year ending March 31, 2022 was USD 55.29 M, a 132.34% change year over year.
Roivant Sciences Ltd. Revenue for the year ending March 31, 2021 was USD 23.80 M, a -64.85% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqGS: ROIV

Roivant Sciences Ltd.

CEO	Mr. Matthew Gline
IPO Date	Dec. 8, 2020
Location	United Kingdom
Headquarters	11-12 St. James's Square
Employees	908
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Key trends

Past 5 years